Drugs / 177Lu-DTPA-SC16.56
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06941480 | Jun 2026 → May 2030 expected | lung neuroendocrine neoplasm, neuroendocrine carcinoma, prostate neuroendocrine neoplasm | Memorial Sloan Kettering Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-DTPA-SC16.56 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06941480 ↗ |